APhA-APRS ESAS Keynote: Pharmacogenomic Testing: The Economics of Individualized Medicine


Pharmacogenetics testing: is it ready for prime time in the care of your patients? Researchers have discovered targeted therapies, like breast cancer treatment and Hepatitis C medications, using the genetic variances from the Human Genome Project. In addition, genetic testing has allowed practitioners to choose certain drug and dose combinations that are tailored to an individual patient’s needs, minimizing side effects and improving outcomes. Take part in this keynote presentation designed to discuss the economic and policy impacts of genetic testing and its use in therapeutic decision-making.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to: 

  1. Describe the basics of pharmacogenomics and pharmacogenomic testing.
  2. Recognize the impact of genetic testing on therapy plan development.
  3. Discuss the economic impact of genetic testing and future trends for drug development.
Kristin Weitzel, FAPHA
Clinical Professor
Department of Pharmacy Practice
Beth Devine, PharmD,MBA,PhD
University of Washington
Learning Level: Level 2
Pathway: Day of Science
Track: Integrating Science into Practice
Session Time Slot(s): 
Friday, March 22
8:00 AM - 9:30 AM
Washington State Convention Center - Room 611-612
ACPE Pharmacist: 0202-0000-19-012-L04-P
CEUs Pharmacist: .15
Activity Type: